Spelling suggestions: "subject:"psychopharmacology.""
21 |
The effects of [Greek capital delta]9 THC on nervous function in Aplysia /Acosta-Urquidi, Juan January 1974 (has links)
No description available.
|
22 |
The effects of [Greek capital delta]9 THC on nervous function in Aplysia /Acosta-Urquidi, Juan January 1974 (has links)
No description available.
|
23 |
The effects of age on urinary bladder function in the male rat : response to pharmacological agents /Chun, Alexa L. January 1987 (has links)
No description available.
|
24 |
IN VITRO EFFECTS OF ACRYLAMIDE AND ITS ANALOGUES ON DORSAL ROOT GANGLIA.McKean, Deborah Lea. January 1984 (has links)
No description available.
|
25 |
The Long-term Neurocognitive Development of Children Exposed to Above Manufacturer Recommended Doses of Diclectin In UteroCarey, Nathalie 21 November 2012 (has links)
Nausea and vomiting of pregnancy (NVP) affects up to 90% of pregnancies. Diclectin (doxylamine/pyridoxine) is the only anti-emetic approved in Canada for NVP, at a maximum dose of 4 tablets/day. However, some women receive higher doses, up to 12 tablets/day. In this study we compared the neurocognitive development of children from four mother-child groups: (1) NVP and >4 tablets Diclectin, (2) NVP and ≤ 4 tablets Diclectin, (3) NVP and no treatment and (4) no NVP. Children received a full age-appropriate psychological assessment. All groups scored in the normal range for IQ and cognition tests. The Diclectin-exposed groups scored significantly higher on a small number of subtests, but none of the differences could be considered clinically significant. No dose-dependent effects were observed. Above manufacturer recommended doses of Diclectin do not appear to harm neurodevelopment and should be considered safe for the treatment of NVP.
|
26 |
The Long-term Neurocognitive Development of Children Exposed to Above Manufacturer Recommended Doses of Diclectin In UteroCarey, Nathalie 21 November 2012 (has links)
Nausea and vomiting of pregnancy (NVP) affects up to 90% of pregnancies. Diclectin (doxylamine/pyridoxine) is the only anti-emetic approved in Canada for NVP, at a maximum dose of 4 tablets/day. However, some women receive higher doses, up to 12 tablets/day. In this study we compared the neurocognitive development of children from four mother-child groups: (1) NVP and >4 tablets Diclectin, (2) NVP and ≤ 4 tablets Diclectin, (3) NVP and no treatment and (4) no NVP. Children received a full age-appropriate psychological assessment. All groups scored in the normal range for IQ and cognition tests. The Diclectin-exposed groups scored significantly higher on a small number of subtests, but none of the differences could be considered clinically significant. No dose-dependent effects were observed. Above manufacturer recommended doses of Diclectin do not appear to harm neurodevelopment and should be considered safe for the treatment of NVP.
|
27 |
Tyrosine hydroxylase-green fluorescence protein transgenic zebrafish as a biosensor and animal model for nicotine and ketamine drug effectsSuen, Fung Ki 01 January 2012 (has links)
No description available.
|
28 |
The effects of 3-mercaptopropionic acid on the cardiovascular system and the content of GABA in specific areas of the brain: further evidence for GABAergic involvement in central cardiovascular controlAlsip, Nancy L. January 1984 (has links)
This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu). / A role has been proposed for the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in central cardiovascular control. This proposa 1 was based on the cardiovascular effects of agents which block or mimic the action of GABA on the post-synaptic membrane. This dissertation reported the cardiovascular effects of 3-mercaptopropionic acid (3-MP), an agent which inhibits GABA biosynthesis in the pre-synaptic nerve terminal in anesthetized guinea pigs. 3-MP interrupts GABAergic transmission by decreasing the amount of GABA in the brain. The effect of 3-MP on mean arterial pressure, heart rate and barorflex-induced bradycardia was determined as well as the mechanism(s) involved in observed changes. The content of GABA in four regions of the brain (hypothalamus, medulla, cerebellum and occipital cortex) was determined at the end of each experiment. In anesthetized guinea pigs, 3-MP (195 mg/kg, i.p.) elicited a biphasic response (Type I) in the majority of animals. This response consisted of sympathetically-mediated hypertension and tachycardia superseded by vagally-mediated bradycardia. The other response (Type II) consisted of only the sympathetically-mediated effects. The Type II response was associated with animals in which the vagus nerves were functionally impaired. In all brain regions measured, the GABA levels of both Types I and II were significantly lower than those of control animals. The sympathetically-mediated effects of 3-MP were reversed by chlordiazepoxide, a GABA-facilitory agent. Therefore, the 3-MP-induced cardiovascular effects appeared to reflect GABAergic activity in the bra in which resulted from a reduction of GABA content. The two phases of the Type I response may have resulted from a reduction of GABA content in specific brain regions. A reduction in hypothalamic GABA levels appeared to be related to the sympathetic activation and a reduction in medullary GABA levels appeared to be related to the vagal activation. In unparalyzed animals, 3-MP elicited convulsive movements as well as the described effects on the cardiovascular system. The centrally acting anticonvulsant phenytoin stopped 3-MP-induced motor manifestations of seizure activity without altering either blood pressure or heart rate. Therefore, the cardiovascular effects of 3-MP appeared to occur independent of the convulsive effect of this agent. These results support the hypothesis of GABAergic involvement in the central control of autonomic outflow to the cardiovascular system. The inability of phenytoin to reverse the cardiovascular effects of 3-MP suggests that these effects were independent of 3-MP-induced seizures.
|
29 |
The neuropharmacology of attentional modulation in primate visual cortexVeith, Vera Katharina 04 March 2016 (has links)
No description available.
|
30 |
Efeito da proteção desencadeada pelo estrógeno na linhagem C6 de glioma de rato. / Effect of protection triggered by estrogen on rat glioma cell line C6.Franco, Lucas Augusto Moysés 24 February 2011 (has links)
Evidências sugerem que as células da glia desempenham um papel importante na sinalização neuronal e na resposta inflamatória no Sistema Nervoso Central (SNC). Respostas inflamatórias crônicas, bem como a ativação da glia estão associadas com doenças neurodegenerativas, como Parkinson e Alzheimer. A inflamação crônica pode ser modulada por altas concentrações de espécies reativas de oxigênio (ERO) que potencializam esse quadro. O estrógeno (E2) é bem conhecido por suas ações neuroprotetoras que podem ser exercidas via receptores clássicos (ESR1, ESR2), não-classicos (GPER-1) ou ainda por sua ação antioxidante, proveniente da alta semelhança com as moléculas dos flavonóides. A ação do E2 no SNC é relevante uma vez que este hormônio está relacionado com a modulação da memória, neurogênese e plasticidade. Este trabalho tem como objetivo investigar o papel protetor do E2 em linhagem de células C6 de glioma de ratos em um modelo de estresse oxidativo que induz morte celular pela exposição a concentrações tóxicas de peróxido de hidrogênio (H2O2). Ensaios de PCR, Western Blot e de imunofluorescência confirmaram a presença e funcionalidade dos receptores ESR1, enquanto ensaios de PCR mostraram a presença do RNAm para o GPER-1 em células C6. Nossos resultados confirmaram que a H2O2 induz morte nas células C6 e o pré-tratamento com E2 (por 24 horas) e G1 (por 20 minutos) diminuiu a toxicidade da H2O2 de maneira dose-dependente, gerando aumento de viabilidade celular. Estes resultados destacam o envolvimento do E2 e seus receptores na prevenção do dano celular em células da glia. Além disso, eles também sugerem que o rápido efeito protetor do E2 parece estar associado com a sinalização rápida do E2 via GPER-1. Por Western blot e RT-PCR avaliamos a participação da via AKT-CREBBDNF frente aos tratamentos com E2, moduladores seletivos de estrógeno (SERMs) e G1, onde observamos que estes são capazes de modular a expressão da proteína AKT e os níveis de RNAm para BDNF. / Evidence suggests that glial cells play an important role in neuronal signaling and inflammatory responses in the central nervous system (CNS). Chronic inflammatory responses, as well as activation of glia, are associated with neurodegenerative disorders such as Parkinson´s and Alzheimer´s diseases. Chronic inflammation can be modulated by high concentrations of reactive oxygen species (ROS) that enhance this process. Estrogen (E2) is well known for its neuroprotective actions that can be performed via classical (ESR1, ESR2) and non-classical receptors (GPER-1) or by its antioxidant action due to its high similarity to flavonoids molecules. E2 action in the CNS is relevant as this hormone is associated to memory modulation, neurogenesis and plasticity. This work has as purpose to investigate the protective role of E2 in rat C6 glioma cell lines in a model of oxidative stress that induces cell death by exposure to toxic concentrations of hydrogen peroxide (H2O2). PCR, Western blot and immunofluorescence assays have confirmed the presence and functionality of the ESR1 receptor, while PCR assay has showed the presence of GPER-1 receptor mRNA in C6 cells. Our results confirmed that H2O2 induces cell death and pre-treatment with E2 (24 hours) and G1 (20 minutes) reduces H2O2 toxicity in a dose-dependent way, leading to increased cell viability. These results highlight the involvement of E2 and its receptors in preventing cell damage in glial cells. Moreover, they also suggest that the prompt E2 protective effect seems to be associated to the fast E2 signaling via GPER-1. We also evaluated the involvement of AKT-CREB-BDNF pathway when C6 cells were treated with E2, selective estrogen modulators (SERMs) and G1 by Western blot and RT-PCR assays, and we could notice that they can modulate the expression of AKT protein and BDNF RNAm levels.
|
Page generated in 0.0543 seconds